MA40897A - Unité de dispositif de médicaments contenant de la quinagolide - Google Patents

Unité de dispositif de médicaments contenant de la quinagolide

Info

Publication number
MA40897A
MA40897A MA040897A MA40897A MA40897A MA 40897 A MA40897 A MA 40897A MA 040897 A MA040897 A MA 040897A MA 40897 A MA40897 A MA 40897A MA 40897 A MA40897 A MA 40897A
Authority
MA
Morocco
Prior art keywords
quinagolide
drug
poly
alkylene oxide
block copolymer
Prior art date
Application number
MA040897A
Other languages
English (en)
Other versions
MA40897B1 (fr
Inventor
Saez Joan Carles Arce
Denis Carr
Robert Cochrane
Janet Halliday
Paul Mcdonald
Axel Niclas Petri
Mohammad Qadir
Gouher Rabani
Alistair Ross
Claire Young
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA40897A publication Critical patent/MA40897A/fr
Publication of MA40897B1 publication Critical patent/MA40897B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/001—Combinations of extrusion moulding with other shaping operations
    • B29C48/0021—Combinations of extrusion moulding with other shaping operations combined with joining, lining or laminating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor
    • B29L2031/754—Pessaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention est basée sur l'identification d'une cohorte de copolymères séquencés de polyuréthane qui sont particulièrement adaptés pour utilisation dans des unités médicament-dispositif polymères pharmaceutiques et qui permettent un contrôle amélioré de la libération de médicament. En particulier, l'invention concerne une unité médicament-dispositif polymère comprenant un copolymère séquencé de polyuréthane pouvant être obtenu par réaction conjointement d'un poly(oxyde d'alkylène) ; un composé difonctionnel ; un isocyanate difonctionnel ; et facultativement un copolymère séquencé comprenant des blocs de poly(oxyde d'alkylène) ; et du quinagolide en tant qu'agent actif pharmaceutique. Les unités médicament-dispositif peuvent avoir une application dans le traitement et/ou la prévention de l'endométriose.
MA40897A 2014-11-07 2015-11-05 Unité de dispositif de médicaments contenant de la quinagolide MA40897B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192372.2A EP3017809A1 (fr) 2014-11-07 2014-11-07 Unité de dispositif de médicaments contenant de la quinagolide
PCT/EP2015/075849 WO2016071466A1 (fr) 2014-11-07 2015-11-05 Unité médicament-dispositif contenant du quinagolide

Publications (2)

Publication Number Publication Date
MA40897A true MA40897A (fr) 2017-09-13
MA40897B1 MA40897B1 (fr) 2021-04-30

Family

ID=51951583

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056414A MA56414A (fr) 2014-11-07 2015-11-05 Unité de dispositif de médicaments contenant de la quinagolide
MA40897A MA40897B1 (fr) 2014-11-07 2015-11-05 Unité de dispositif de médicaments contenant de la quinagolide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA056414A MA56414A (fr) 2014-11-07 2015-11-05 Unité de dispositif de médicaments contenant de la quinagolide

Country Status (33)

Country Link
US (2) US20180008535A1 (fr)
EP (3) EP3017809A1 (fr)
JP (2) JP6907120B2 (fr)
KR (1) KR102612852B1 (fr)
CN (2) CN106999422A (fr)
AR (1) AR102571A1 (fr)
AU (2) AU2015341734C1 (fr)
CA (1) CA2966473A1 (fr)
CL (1) CL2017001119A1 (fr)
CO (1) CO2017005578A2 (fr)
DK (1) DK3215118T3 (fr)
EA (2) EA201991882A2 (fr)
ES (1) ES2877973T3 (fr)
HR (1) HRP20210961T1 (fr)
HU (1) HUE054951T2 (fr)
IL (1) IL252088B (fr)
JO (1) JO3561B1 (fr)
LT (1) LT3215118T (fr)
MA (2) MA56414A (fr)
MD (1) MD3215118T2 (fr)
MX (1) MX2017005828A (fr)
MY (1) MY193638A (fr)
PH (1) PH12017550005A1 (fr)
PL (1) PL3215118T3 (fr)
PT (1) PT3215118T (fr)
RS (1) RS62018B1 (fr)
SA (1) SA517381471B1 (fr)
SG (1) SG11201703596SA (fr)
SI (1) SI3215118T1 (fr)
TN (1) TN2017000175A1 (fr)
TW (1) TWI685339B (fr)
UA (1) UA122329C2 (fr)
WO (1) WO2016071466A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896685B2 (en) 2018-10-31 2024-02-13 Amorepacific Corporation Core-shell network structure comprising biopolymer and composition comprising same
KR20210069344A (ko) 2019-12-03 2021-06-11 (주)아모레퍼시픽 바이오 폴리머를 포함하는 효능물질 전달체
WO2023031218A1 (fr) 2021-08-31 2023-03-09 Ferring B.V. Diagnostic et traitement de l'endométriose ectopique

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235988A (en) 1976-12-13 1980-11-25 Imperial Chemical Industries Limited Delivery means for biologically active agents
EP1620060B1 (fr) 2003-04-29 2010-03-24 The General Hospital Corporation Procedes et dispositifs a liberation soutenue de plusieurs medicaments
CA2531640C (fr) 2003-07-10 2013-06-18 Galen (Chemicals) Limited Dispositifs d'administration de medicaments par voie intravaginale
WO2005025549A2 (fr) * 2003-09-10 2005-03-24 Noven Pharmaceuticals, Inc. Dispositif multicouche d'administration transdermique de medicaments
WO2006117608A1 (fr) 2005-04-29 2006-11-09 Ferring International Center S.A. Traitement ou prevention du syndrome d'hyperstimulation ovarienne (ohss) au moyen d'un agoniste de la dopamine
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
SA08290041B1 (ar) 2007-02-01 2012-06-05 فيرينج انترناشونال سنتر اس آيه أدوية من أجل معالجة بطانة الرحم
US20110045076A1 (en) 2008-01-25 2011-02-24 Kiser Patrick F Linear order release polymer
BRPI0906467C1 (pt) * 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
US20100040671A1 (en) 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof
US20100210600A1 (en) * 2009-02-19 2010-08-19 Prelief Inc. Methods and Compositions for Treating Urogenital Disorders
EP2445501A2 (fr) * 2009-06-26 2012-05-02 Ferring B.V. Utilisation de la quinagolide pour le traitement de l'endométriose, du cancer et de la douleur
US20110262347A1 (en) * 2010-04-08 2011-10-27 The Salk Institute For Biological Studies Methods and compositions for enhanced delivery of compounds
WO2012066000A1 (fr) 2010-11-15 2012-05-24 Dsm Ip Assets B.V. Dispositif d'administration de médicament intra-vaginal comportant un copolymère polyuréthane
KR20140074281A (ko) * 2011-07-20 2014-06-17 패트릭 에프. 카이저 약물 전달용 질내 장치
US10137199B2 (en) * 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US10413504B2 (en) * 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
CN106999422A (zh) 2017-08-01
AU2015341734A1 (en) 2017-06-01
JP2017533272A (ja) 2017-11-09
PL3215118T3 (pl) 2021-07-26
PH12017550005A1 (en) 2017-10-18
ES2877973T3 (es) 2021-11-17
EP3892261A1 (fr) 2021-10-13
MA56414A (fr) 2022-05-04
AU2020270480A1 (en) 2020-12-17
CN116212032A (zh) 2023-06-06
JP6907120B2 (ja) 2021-07-21
CO2017005578A2 (es) 2017-08-31
IL252088B (en) 2022-04-01
WO2016071466A1 (fr) 2016-05-12
EA201991882A2 (ru) 2020-01-31
TW201625245A (zh) 2016-07-16
EP3017809A1 (fr) 2016-05-11
JP2021155444A (ja) 2021-10-07
KR102612852B1 (ko) 2023-12-11
EP3215118B1 (fr) 2021-03-17
KR20170080671A (ko) 2017-07-10
DK3215118T3 (da) 2021-06-21
EP3215118A1 (fr) 2017-09-13
SI3215118T1 (sl) 2021-08-31
EA201790898A1 (ru) 2017-11-30
US20180008535A1 (en) 2018-01-11
US20220040094A1 (en) 2022-02-10
EA201790898A8 (ru) 2018-01-31
CA2966473A1 (fr) 2016-05-12
MA40897B1 (fr) 2021-04-30
TWI685339B (zh) 2020-02-21
EA033806B9 (ru) 2019-12-19
MX2017005828A (es) 2017-11-13
PT3215118T (pt) 2021-05-31
IL252088A0 (en) 2017-07-31
EA033806B1 (ru) 2019-11-27
BR112017009476A2 (pt) 2018-01-02
MY193638A (en) 2022-10-21
LT3215118T (lt) 2021-06-10
RS62018B1 (sr) 2021-07-30
HUE054951T2 (hu) 2021-10-28
CL2017001119A1 (es) 2018-01-05
HRP20210961T1 (hr) 2021-09-17
SA517381471B1 (ar) 2022-03-06
MD3215118T2 (ro) 2021-08-31
AU2015341734B2 (en) 2020-08-20
TN2017000175A1 (en) 2018-10-19
UA122329C2 (uk) 2020-10-26
JO3561B1 (ar) 2020-07-05
AU2015341734C1 (en) 2020-12-17
SG11201703596SA (en) 2017-06-29
AR102571A1 (es) 2017-03-08

Similar Documents

Publication Publication Date Title
MA40897A (fr) Unité de dispositif de médicaments contenant de la quinagolide
FR3029790B1 (fr) Microbille d'hydrogel de chitosane
PE20061087A1 (es) Formas farmaceuticas resistente a la rotura con liberacion sostenida
MA37809A1 (fr) Administration de médicament biodégradable pour compositions hydrophobes
MX2013003892A (es) Composicion farmaceutica liquida para el suministro de ingredientes activos.
TN2017000506A1 (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
MA39390B2 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
EA201990949A1 (ru) Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине
AU2019301069A8 (en) Mixing/administration system for vaccines and medicaments
BR112022002289A2 (pt) Composições de curativo líquido e seus usos veterinários
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
MX2019004973A (es) Moduladores de ror gamma.
ZA202006415B (en) Tetrabenazine transdermal delivery device
MA45639B1 (fr) Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase
FR3059550B1 (fr) Traitement des troubles causes par l'alcoolisation foetale (tcaf)
FR3068704B1 (fr) Materiau solide organique antibacterien
MA38871A1 (fr) Complexe lubrifiant pour la bouche
TH1701002526A (th) หน่วยอุปกรณ์ส่งยาที่มีควินาโกไลด์
FR3097758B1 (fr) Dispositif Aérosol Contenant une Composition Comprenant au moins un Polyuréthane, au moins un Polymère Acrylique, au moins un Polymère Crotonique et au moins un Agent Propulseur
CR20220198A (es) Composición farmacéutica que puede usarse para la prevención y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composición farmacéutica
Khor et al. HLA-B* 15: 02 allele association with Carbamazepine-induced Severe Cutaneous Reaction in Malaysian Indian, a pooled-sample analysis and meta-analysis
FR3061178B1 (fr) Peptides antimicrobiens et leurs utilisations
SA119410171B1 (ar) طريقة لمنع أو علاج أو تحسين عدوى ميكروبية
FR3072279B1 (fr) Utilisation de la cloxacilline pour inhiber/ empecher la formation de biofilm
FR3084837B1 (fr) Composition filmogene mucoadhesive et son utilisation pour le traitement des douleurs liees aux poussees dentaires